ESR1 and breast cancer: Although our data suggest that the benefit of continued use of selective inhibitors of CDK4/6 in the acquired resistant setting will be of little or no clinical benefit, combined targeting of CDK4/6 and PI3K/mTOR signaling with hormonal blockade may provide benefit to treatment-naive ER+/HER2− breast cancers.